None listed
Conditions
Brief summary
This study aims to explore whether a low-carbohydrate/ketogenic diet combined with ketone supplementation can improve kidney and metabolic health in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study will assess safety, feasibility, and changes in quality of life, kidney function, and metabolic markers. Participants will receive dietary support via a smartphone app, take a ketone supplement, and use continuous glucose monitoring. The hypothesis is that reducing glucose availability and supporting nutritional ketosis may slow disease progression and improve overall wellbeing in people with ADPKD.
Interventions
Participants will follow a low-carbohydrate/ketogenic dietary program designed to reduce glucose availability and promote nutritional ketosis. This dietary intervention will be supported by the Defeat Diabetes App, which provides structured meal plans, educational content, and behavioural support to facilitate adherence. Prior to commencing the dietary intervention and exogenous ketone supplementation, participants will attend an initial consultation session with a member of the research team. This session will last approximately 30 minutes and will include an introduction to the dietary program, guidance on using the Defeat Diabetes App, and an opportunity for participants to ask questions and clarify any concerns. During this session, participants will also be introduced to continuous glucose monitoring (CGM) devices to track real-time glucose levels throughout the intervention. The CGM system includes an associated mobile app that allows participants to view their glucose data, identify trends, and receive alerts. This data will support dietary behaviour change by helping participants understand the impact of food choices on glucose levels. In addition to dietary changes, participants will receive exogenous ketone supplementation using KetoCitra®, a medical food formulation designed for individuals with polycystic kidney disease. The supplement will be administered orally, at a dose of one scoop (approximately 10g) twice daily, mixed with water, for the duration of the 12-week intervention period. Participants will also use continuous glucose monitoring (CGM) devices to track real-time glucose levels and support dietary behaviour change. CGM data will be reviewed by the research team and used to provide personalised feedback via the app.
Sponsors
Study design
Eligibility
Inclusion criteria
Adult patients with a diagnosis of ADPKD Adult patients providing informed consent
Exclusion criteria
Inabilitly to provide informed consent Pregnancy or breastfeeding